Erschienen in:
01.04.2012 | PHASE II STUDIES
Treatment of bevacizumab-induced hypertension by amlodipine
verfasst von:
Olivier Mir, Romain Coriat, Stanislas Ropert, Laure Cabanes, Benoit Blanchet, Sandra Camps, Bertrand Billemont, Bertrand Knebelmann, François Goldwasser
Erschienen in:
Investigational New Drugs
|
Ausgabe 2/2012
Einloggen, um Zugang zu erhalten
Summary
Background Hypertension is a common toxicity of anti-VEGF agents, but its optimal treatment remains to define. This study aimed to describe the efficacy and tolerability of amlodipine, a calcium channel blocker, in patients with metastatic malignancies treated with bevacizumab, a humanized monoclonal antibody to VEGF. Patients and methods One hundred and eighty-seven patients with advanced or metastatic NSCLC, colorectal or ovarian cancer receiving bevacizumab (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks) and chemotherapy were eligible for this analysis. Blood pressure was measured at home twice daily according to international guidelines. Patients received amlodipine 5 mg daily for grade ≥2 bevacizumab-induced hypertension. Results Twenty-six patients received amlodipine 5 mg daily for de novo hypertension (group A), and another 10 patients received amlodipine for exacerbation of previously existing hypertension (group B). Hypertension was controlled within 7 days under amlodipine in 23/26 (88.5%, 95%CI: 76.2–100) patients in group A, and 8/10 (80%, 95%CI: 55.2–100) patients in group B, with a favourable toxicity profile. Conclusions Amlodipine 5 mg daily appears safe and efficient for the treatment of hypertension in patients receiving bevacizumab at a dose-intensity of 2.5 mg/kg/week. Further prospective studies are warranted to confirm these results.